Manufacturing discipline for translational science
Medical devices and biologics — from first GMP build to commercial readiness
RedRock exists for the moment translational science has to reach patients - reproducible dose/response at clinical scale that will carry through to commercial scale. Manufacturing strategy is how a breakthrough survives the regulatory and financial transition to commercial production. RedRock builds the manufacturing discipline that treats sterility and function as a single problem, protecting both the science and the momentum behind it.
PROOF
5Ă— increase in deviation-free yields. A complex eight-week aseptic bioprocess was failing, and the new 3D culture launch took the blame. System-level analysis found the real constraint downstream in media and buffer preparation. Pivotal trial completed on time, no added headcount, no capital spend.
2.5-year plan compressed to 6 months. A vascular tissue engineering startup faced a two-and-a-half-year path to first-in-man-enabling data. Rebuilding the sequence — running large-animal work out of an available facility during COVID, and converting the lab to GMP in parallel rather than serially — delivered the data in six months.
50% throughput increase with 20% fewer staff. Replacing reactive dispatch with a fixed schedule made manpower plannable. When the contract overflow sterilizer went down for eight weeks, 100% of the load ran internally with zero interruption.
Recent Projects:
